FDA review summary of patient-reported outcome results for ibrutinib in the treatment of chronic graft versus host disease

King-Kallimanis, BL; Wroblewski, T; Kwitkowski, V; De Claro, RA; Gwise, T; Bhatnagar, V; Farrell, AT; Kluetz, PG

King-Kallimanis, BL (corresponding author), US FDA, Oncol Ctr Excellence, Bldg 22,10903 New Hampshire Ave, Silver Spring, MD 20993 USA.; King-Kallimanis, BL (corresponding author), US FDA, WO22 Room 2372,10903 New Hampshire Ave, Silver Spring, MD 20993 USA.

QUALITY OF LIFE RESEARCH, 2020; 29 (7): 1903

Abstract

Purpose On August 2, 2017, the Food and Drug Administration approved ibrutinib (IMBRUVICA) for the treatment of patients with chronic graft versus hos......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索